Asenapine is a second-generation antipsychotic approved in Europe for treating moderate-to-severe manic episodes in adults affected by type I bipolar disorder (BD-I). We aimed to compare its efficacy in psychiatric inpatients with BD-I, with or without substance use disorder (SUD). We administered flexible asenapine doses ranging from 5–20 mg/day to 119 voluntarily hospitalized patients with Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) BD-I diagnosis, with or without SUD. Patients were assessed with clinician-rated questionnaires [i.e. Brief Psychiatric Rating Scale (BPRS), Young Mania Rating Scale (YMRS), Hamilton Depression Rating Scale (HDRS), Hamilton Anxiety Rating Scale (HARS), and Global Assessment of Functioning (GAF)]. Assessments were carried out at baseline (T0, prior to treatment), and 3 (T1), 7 (T2), 15 (T3), and 30 days (T4) after starting treatment for all clinical scales and at T0 and T4 for the GAF. Patients improved on all scales (p < 0.001) across all timepoints, as shown both by paired-sample comparisons and by applying a repeated-measures, generalized linear model (GLM). Patients without comorbid SUD showed greater reductions in BPRS scores at T2 and T3, greater reduction in YMRS scores at T3, and lower HARS scores at all timepoints. HDRS scores did not differ between the two groups at any timepoint. However, the reduction in HARS scores in the comorbid group was stronger than in the BD-I only group, albeit not significantly. Side effects were few and mild-to-moderate. The open-label design and the relatively short observation period may expose to both type I and type II statistical errors (false positive and false negatives). Asenapine showed effectiveness and safety in hospitalized BD-I patients. Its effect was stronger in patients without comorbid SUD.
Crying may be a beneficial experience and reflect a patients' involvement in the therapeutic work, as well as a potential indicator of the healing process. This study explored the relationships between patients' crying experience in therapy, their perception of working alliance and therapeutic change, as well as considering the role of attachment styles. One hundred six patients completed a survey about crying in psychotherapy and self-report measures for assessing working alliance, therapeutic change, and attachment styles. Concerning general crying experiences, results showed that when patients' crying (even if painful) was followed by more positive or less negative emotions (i.e., a sense of relief), they perceived the working alliance more positively and therapeutic change as enhanced. Similarly, regarding their most recent crying episode, patients' feeling of crying as a positive (albeit often painful) experience was related with a better perception of working alliance and therapeutic change. In relation to variance explained by patient attachment style, our results are quite limited and secondary to the findings on crying-related experiences, working alliance and therapeutic change. However, when attachment style did contribute significantly to a regression model, results indicated that for patients with high dismissing attachment concerns, crying in a context of a good working alliance may represent both a useful process for reducing negative emotions and an indicator of good therapeutic outcome. Clinical and empirical implications are discussed in terms of the relevance of the therapeutic crying experience on the quality of working alliance and therapeutic change. (PsycInfo Database Record (c) 2021 APA, all rights reserved).
Studies comparing organized (O) and unresolved/disorganized (UD) attachment have consistently shown structural and functional brain abnormalities, although whether and how attachment patterns may affect resting state functional connectivity (RSFC) is still little characterized. Here, we investigated RSFC of temporal and limbic regions of interest for UD attachment. Participants’ attachment was classified via the Adult Attachment Interview, and all participants underwent clinical assessment. Functional magnetic resonance imaging data were collected from 11 UD individuals and seven matched O participants during rest. A seed-to-voxel analysis was performed, including the anterior and the posterior cingulate cortex, the bilateral insula, amygdala and hippocampus as seed regions. No group differences in the clinical scales emerged. Compared to O, the UD group showed lower RSFC between the left amygdala and the left cerebellum (lobules VIII), and lower functional coupling between the right hippocampus and the posterior portion of the right middle temporal gyrus. Moreover, UD participants showed higher RSFC between the right amygdala and the anterior cingulate cortex. Our findings suggest RSFC alterations in regions associated with encoding of salient events, emotion processing, memories retrieval and self-referential processing in UD participants, highlighting the potential role of attachment experiences in shaping brain abnormalities also in non-clinical UD individuals.
1 April 2015 in Journal of Clinical Psychopharmacology